• Our Solution
    • Physicians
    • Patients
  • About Artrya
    • Who we are
    • Board of Directors
    • Careers
  • Investor Relations
    • Overview
    • ASX Announcements
    • Corporate Governance
    • Company Research
  • Contact Us
Request a demonstration

Change of Director’s Interest Notice – Bernie Ridgeway

Quarterly Results Conference Call

Quarterly Activity Report and Appendix 4C for Q2 FY22

Notification regarding unquoted securities – AYA

Artrya appoints Dr Jacque Sokolov as United States Advisor

Artrya Update December 2021

Notice of Initial Substantial Holder – John Barrington

Initial Director’s Interest Notice – John Konstantopoulos

Notice of Initial Substantial Holder – John Konstantopoulos

Notice of Initital Substantial Holder – Artrya Limited

Previous 1 … 15 16 17 18 19 20 Next

Precise diagnosis. Personalized treatment.
Preventative care.

Choose Artrya as your trusted clinical partner.

Contact us today
Coronary artery disease.
We see you.

Sign up to our newsletter

Request a Demo
Contact Us

About Artrya
Investor Relations

Location
1257 Hay Street, West Perth, 6005
Follow us
X
LinkedIn

Salix Coronary Anatomy is listed on the Australian Register of Therapeutic Goods, ID 347719. Salix Central USA product (K243038) is cleared in the USA. For the availability of Salix in The EU, UK, or other jurisdictions, please contact us.

© 2025, Artrya. All rights reserved. Privacy Policy Terms and Conditions Indications for Use